同步财经SNDX
Syndax Pharmaceuticals Inc : Guggenheim Cuts Target Price to $32 From $35
时间：2025-02-13 19:49:24 市场： 美股 综合
Incyte and Syndax Announce U.S. Food and Drug Administration (FDA) Approval of Niktimvo™ (Axatilimab-Csfr) 9 Mg and 22 Mg Vial Sizes
时间：2025-01-16 06:34:35 市场： 美股 综合
Incyte Corp - Niktimvo Expected to Be Available in U.S. in Early February
时间：2025-01-16 06:34:35 市场： 美股 综合
Syndax Pharmaceuticals Inc - Catherine Madigan to Cease as Chief Medical Officer
时间：2024-12-21 06:01:29 市场： 美股 综合
Syndax Announces Additional Positive Data for Revuforj® (Revumenib) From Augment-101 Trial in Relapsed or Refractory Mnpm1 Aml and Beat Aml Frontline Combination Trial
时间：2024-12-09 20:32:36 市场： 美股 综合
Syndax Presents Positive Revuforj® (Revumenib) Data in Acute Leukemias From Multiple Trials, Including the Save Combination and Augment-101 Trials, at 66TH Ash Annual Meeting
时间：2024-12-08 07:15:43 市场： 综合 美股
Syndax Announces FDA Approval of Revuforj® (Revumenib), the First and Only Menin Inhibitor to Treat Adult and Pediatric Patients With Relapsed or Refractory Acute Leukemia With a Kmt2a Translocation
时间：2024-11-16 06:29:37 市场： 美股 综合
Syndax Pharmaceuticals Inc - Revuforj 110 and 160 Mg Tablets Expected to Be Available for Order in U.S. in November
时间：2024-11-16 06:29:37 市场： 美股 综合
FDA Approves Revumenib for Relapsed or Refractory Acute Leukemia With a Kmt2a Translocation
时间：2024-11-16 04:59:43 市场： 美股 综合
Syndax Pharmaceuticals, Inc. : H.c. Wainwright Raises Target Price to $49 From $47
时间：2024-11-12 23:59:30 市场： 美股 综合